GE HealthCare fully acquires Japanese pharma company
by 
GE HealthCare has acquired full ownership of a leading radiopharmaceutical firm Nihon Medi-Physics, that generated $183 million in revenue last year. NMP’s product portfolio includes GE HealthCare radiopharmaceuticals delivered across neurology, cardiology and oncology. Among them are Vizamyl, used in Alzheimer’s treatment; DaTscan, for evaluating patients with suspected Parkinson’s or dementia; and Myoview, for assessing possible coronary artery disease.
“As the third largest pharmaceutical market in the world, and amongst the leading countries by number of cyclotrons, Japan is on a path to becoming a leader in the $7 billion molecular imaging global market and a center of excellence for Asian markets,” Kevin O’Neill, president and CEO of GE HealthCare’s pharmaceutical diagnostics segment, said in an announcement shared late Sunday. “NMP will play a key role in that journey, including bringing its deep expertise and scale to global innovators looking to bring novel products to the Japan market and beyond.”
The two companies hope to close the transaction in early 2025, subject to regulatory approval. GE HealthCare expects the transaction to be neutral to adjusted earnings in the first year and accretive thereafter.
Visit our upcoming pharma conferences – https://virtueinsight.com/upcoming-conferences/